Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on February 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Ultragenyx Pharmaceutical Trading Down 3.5%

Shares of RARE stock traded down $0.77 during trading hours on Thursday, hitting $21.44. The company’s stock had a trading volume of 700,394 shares, compared to its average volume of 2,461,373. The stock has a market cap of $2.07 billion, a PE ratio of -3.67 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.41 and a 12-month high of $42.37. The company has a 50 day moving average of $23.08 and a 200 day moving average of $28.93.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). The business had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company’s revenue for the quarter was up 25.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.39) earnings per share. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 1,635 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $22.40, for a total transaction of $36,624.00. Following the completion of the transaction, the chief financial officer directly owned 85,034 shares of the company’s stock, valued at approximately $1,904,761.60. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Eric Crombez sold 7,029 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $160,261.20. Following the completion of the transaction, the executive vice president owned 76,301 shares of the company’s stock, valued at $1,739,662.80. This represents a 8.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 104,958 shares of company stock valued at $2,394,858. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Late‑stage gene‑therapy data showed improved control of ammonia levels in patients with a rare inherited disorder — a clinically meaningful result that supports the program’s value and potential commercial upside. Read More.
• Neutral Sentiment: Management gave investor presentations at the Leerink Global Healthcare and Barclays Global Healthcare conferences this week (transcripts available). These presentations recap pipeline strategy and commercial plans but did not contain new regulatory or financial milestones that would immediately change valuation. Read More. Read More.
• Negative Sentiment: Multiple law firms and shareholder‑alert services issued class‑action notices and lead‑plaintiff reminders tied to a securities lawsuit alleging investor harm (class period Aug 3, 2023–Dec 26, 2025). Firms named in notices include Pomerantz, Schall, DJS, Rosen, Faruqi & Faruqi, Levi & Korsinsky, Bronstein Gewirtz & Grossman, and others — one firm specifically flagged potential control‑person claims naming the CEO and CMO. The wave of filings/solicitations raises litigation overhang and potential settlement exposure, which is likely weighing on the stock. Read More.

Analyst Ratings Changes

RARE has been the topic of a number of recent research reports. HC Wainwright lowered their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Wells Fargo & Company dropped their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 30th. Leerink Partners cut their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Finally, Jefferies Financial Group lowered their price target on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday, December 30th. Sixteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $68.29.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently made changes to their positions in RARE. Covestor Ltd boosted its stake in shares of Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the period. Huntington National Bank lifted its holdings in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares in the last quarter. Xponance Inc. boosted its position in Ultragenyx Pharmaceutical by 3.1% in the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 406 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Ultragenyx Pharmaceutical by 2.3% in the second quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock worth $690,000 after acquiring an additional 434 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 7.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,783 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 441 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.